Business
Leveljump Acquires 23.8% Interest in Shaw Lens and Shaw Vision
Toronto, Ontario--(Newsfile Corp. - August 31, 2021) - Leveljump Healthcare Corp. (TSXV: JUMP)...
About this update from Leveljump Healthcare Corp.
[{"type":"text","content":"Leveljump Acquires 23.8% Interest in Shaw Lens and Shaw VisionToronto, Ontario--(Newsfile Corp. - August 31, 2021) - Leveljump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) (\"Leveljump\" or the \"Company\"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has acquired 23.8% of the issued and outstanding shares of each of Shaw Vision Inc. (\"Shaw Vision\") and Shaw Lens Inc. (\"Shaw Lens\") from a minority shareholder (the \"Shaw Acquisition\").The aggregate purchase price of the Shaw Acquisition is $129,500 and will be paid through issuance of 350,000 common shares of the Company (\"JUMP Shares\") at a deemed issuance price of $0.28 per JUMP Share and 350,000 non-transferable common share purchase warrants of the Company (\"JUMP Warrants\"). Each JUMP Warrant entitles the holder to purchase one common share of the Company at an exercise price of $0.30 per share prior to December 31, 2023. The Shaw Acquisition is an arm's length transaction. There are no finder's fees payable.The Shaw Acquisition has been approved by the boards of Shaw Vision and Shaw Lens. Closing of the Shaw Acquisition is subject to the final consent of the TSX Venture Exchange.All securities issued will be subject to a hold period of four months and one day pursuant to applicable securities laws.Both Shaw Vision Inc. and Shaw Lens Inc. are Toronto-based privately owned federal corporations.About Shaw Lens and Shaw VisionShaw Lens holds a U.S. patent protected lens technology that can solve a condition for people who wear glasses, known as aniseikonia. It is a condition that causes each eye to perceive the size of objects differently. Issues related can include headaches, double vision, disorientation or dizziness, tearing, eye pain or fatigue, sensitivity to light, visual acuity issues and trouble reading, as well as nausea…according to the Columbia University Department of Ophthalmology… \"20-30% of the general spectacle wearing population may have a measurable amount of aniseikonia.\" The potential market size for corrective lenses for aniseikonia is over 800 million people that may be currently living with some degree of aniseikonia and its relative effects. More information about Shaw can be found at www.shawlens.comQuotes from JUMP CEO and Shaw CEO\"The Shaw Lens has proven to be effective with posit...